Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Von Herrath

Showing results (1-10 of 133) with videos related to

Pageof 14
Sort By:
Idrugs : the Investigational Drugs Journal|March 16, 2004
New trends in immunosuppression--sixth international congress. New drug candidates. 5-8 February 2004, Salzburg, AustriaMatthias von Herrath
Novartis Foundation Symposium|February 11, 2009
Defining optimal immunotherapies for type 1 diabetes. IntroductionMatthias von Herrath
Nature|May 30, 2009
Diabetes: A virus-gene collaborationMatthias von Herrath
Nature|May 13, 2005
Immunology: insulin trigger for diabetesMatthias von Herrath
Diabetes|December 31, 2008
Can we learn from viruses how to prevent type 1 diabetes?: the role of viral infections in the pathogenesis of type 1 diabetes and the development of novel combination therapiesMatthias von Herrath
Immunotherapy|July 20, 2010
Combination therapies for type 1 diabetes: why not now?Matthias von Herrath
Current Opinion in Investigational Drugs (London, England : 2000)|November 2, 2005
E1-INT (Transition Therapeutics/Novo Nordisk)Matthias von Herrath
Human Vaccines|December 16, 2010
Type 1 diabetes vaccine development: animal models vs. humansTobias Boettler, Matthias von Herrath
International Immunopharmacology|July 30, 2010
Immunotherapy of type 1 diabetes--how to rationally prioritize combination therapies in T1DTobias Boettler, Matthias von Herrath
The Review of Diabetic Studies : RDS|May 12, 2007
Immunotherapy after recent-onset type 1 diabetes: combinatorial treatment for achieving long-term remission in humans?Damien Bresson, Matthias von Herrath
Pageof 14

Showing results (1-10 of 133) with videos related to

Sort By:
Pageof 14
Idrugs : the Investigational Drugs Journal|March 16, 2004
New trends in immunosuppression--sixth international congress. New drug candidates. 5-8 February 2004, Salzburg, AustriaMatthias von Herrath
Novartis Foundation Symposium|February 11, 2009
Defining optimal immunotherapies for type 1 diabetes. IntroductionMatthias von Herrath
Nature|May 30, 2009
Diabetes: A virus-gene collaborationMatthias von Herrath
Nature|May 13, 2005
Immunology: insulin trigger for diabetesMatthias von Herrath
Diabetes|December 31, 2008
Can we learn from viruses how to prevent type 1 diabetes?: the role of viral infections in the pathogenesis of type 1 diabetes and the development of novel combination therapiesMatthias von Herrath
Immunotherapy|July 20, 2010
Combination therapies for type 1 diabetes: why not now?Matthias von Herrath
Current Opinion in Investigational Drugs (London, England : 2000)|November 2, 2005
E1-INT (Transition Therapeutics/Novo Nordisk)Matthias von Herrath
Human Vaccines|December 16, 2010
Type 1 diabetes vaccine development: animal models vs. humansTobias Boettler, Matthias von Herrath
International Immunopharmacology|July 30, 2010
Immunotherapy of type 1 diabetes--how to rationally prioritize combination therapies in T1DTobias Boettler, Matthias von Herrath
The Review of Diabetic Studies : RDS|May 12, 2007
Immunotherapy after recent-onset type 1 diabetes: combinatorial treatment for achieving long-term remission in humans?Damien Bresson, Matthias von Herrath
Pageof 14